Kelyniam Global Releases Strong Q2 Financials
Kelyniam Global (OTC: KLYG), a custom cranial implant manufacturer, reported strong financial results for the first half of 2024. The company saw significant improvements across key metrics:
- Total revenue increased by 49.01% to $1,709,239
- Gross margin grew 52.7% to $1,330,965
- Operating profit reached $172,093, up from a loss of $229,345
- EBITDA improved to $197,355 from a loss of $204,691
The company attributes this growth to increased sales, efficiency improvements, and reduced expenses. Kelyniam's patented integrated fixation in PEEK implants and CustomizedBone™ hydroxyapatite implants gained market acceptance. The company also held its annual shareholder meeting, participated in industry events, and announced FDA clearance for a partner product.
Kelyniam Global (OTC: KLYG), un produttore di impianti cranici su misura, ha riportato risultati finanziari solidi per il primo semestre del 2024. L'azienda ha registrato miglioramenti significativi in tutti i principali indicatori:
- Il fatturato totale è aumentato del 49,01% a $1.709.239
- Il margine lordo è cresciuto del 52,7% a $1.330.965
- L'utile operativo ha raggiunto $172.093, in crescita rispetto a una perdita di $229.345
- L'EBITDA è migliorato a $197.355 rispetto a una perdita di $204.691
L'azienda attribuisce questa crescita a un aumento delle vendite, miglioramenti dell'efficienza e una riduzione delle spese. Il fissaggio integrato brevettato nei impianti in PEEK e gli impianti CustomizedBone™ in idrossiapatite hanno guadagnato accettazione nel mercato. Kelyniam ha anche tenuto l'assemblea annuale degli azionisti, ha partecipato a eventi del settore e ha annunciato l'approvazione della FDA per un prodotto partner.
Kelyniam Global (OTC: KLYG), un fabricante de implantes craneales personalizados, informó resultados financieros sólidos para la primera mitad de 2024. La compañía vio mejoras significativas en métricas clave:
- Los ingresos totales aumentaron un 49.01% a $1,709,239
- El margen bruto creció un 52.7% a $1,330,965
- El beneficio operativo alcanzó $172,093, en comparación con una pérdida de $229,345
- El EBITDA mejoró a $197,355 desde una pérdida de $204,691
La empresa atribuye este crecimiento a un aumento en las ventas, mejoras en la eficiencia y reducción de gastos. La fijación integrada patentada en implantes de PEEK y los implantes CustomizedBone™ de hidroxiapatita ganaron aceptación en el mercado. Kelyniam también celebró su reunión anual de accionistas, participó en eventos de la industria y anunció la aprobación de la FDA para un producto asociado.
Kelyniam Global (OTC: KLYG), 맞춤형 두개골 임플란트 제조업체가 2024년 상반기 강력한 재무 성과를 보고했습니다. 이 회사는 주요 지표에서 상당한 개선을 보였습니다:
- 총 수익이 49.01% 증가하여 $1,709,239에 달함
- 총 마진이 52.7% 증가하여 $1,330,965에 달함
- 운영 이익이 $172,093에 도달, 이전의 $229,345 손실에서 개선됨
- EBITDA가 $197,355로 개선되어 이전의 $204,691 손실에서 회복됨
회사는 이러한 성장을 매출 증가, 효율성 개선, 비용 절감에 기인한다고 설명했습니다. Kelyniam의 특허 받은 PEEK 임플란트의 통합 고정 및 CustomizedBone™ 하이드록시아파타이트 임플란트는 시장의 인정을 받았습니다. 이 회사는 또한 연례 주주총회를 개최하고, 산업 행사에 참여했으며, 파트너 제품에 대한 FDA 승인을 발표했습니다.
Kelyniam Global (OTC: KLYG), un fabricant d'implants crâniens sur mesure, a rapporté de solides résultats financiers pour la première moitié de 2024. L'entreprise a connu des améliorations significatives dans tous les indicateurs clés :
- Le chiffre d'affaires total a augmenté de 49,01 % pour atteindre 1 709 239 $
- La marge brute a crû de 52,7 % pour atteindre 1 330 965 $
- Le bénéfice d'exploitation a atteint 172 093 $, contre une perte de 229 345 $
- L'EBITDA s'est amélioré à 197 355 $, après avoir subi une perte de 204 691 $
L'entreprise attribue cette croissance à l'augmentation des ventes, aux améliorations de l'efficacité et à la réduction des dépenses. Le système de fixation intégré breveté dans les implants en PEEK et les implants CustomizedBone™ en hydroxyapatite ont gagné en acceptation sur le marché. Kelyniam a également tenu sa réunion annuelle des actionnaires, participé à des événements de l'industrie et annoncé l'approbation de la FDA pour un produit partenaire.
Kelyniam Global (OTC: KLYG), ein Hersteller von maßgeschneiderten Schädelimplantaten, berichtete über starke Finanzzahlen für das erste Halbjahr 2024. Das Unternehmen verzeichnete erhebliche Verbesserungen in allen wichtigen Kennzahlen:
- Der Gesamterlös stieg um 49,01% auf $1.709.239
- Die Bruttogewinnspanne wuchs um 52,7% auf $1.330.965
- Der Betriebsergebnis erreichte $172.093, ein Anstieg von einem Verlust von $229.345
- Das EBITDA verbesserte sich auf $197.355 von einem Verlust von $204.691
Das Unternehmen führt dieses Wachstum auf gestiegene Verkäufe, Effizienzverbesserungen und reduzierte Ausgaben zurück. Kelyniams patentierte integrierte Fixierung in PEEK-Implantaten und die CustomizedBone™-Hydroxyapatit-Implantate fanden im Markt Akzeptanz. Außerdem hielt die Firma ihre jährliche Hauptversammlung der Aktionäre ab, nahm an Branchenveranstaltungen teil und gab die FDA-Zulassung für ein Partnerprodukt bekannt.
- Revenue increased by 49.01% to $1,709,239
- Gross margin grew by 52.7% to $1,330,965
- Operating profit improved by $401,438 to $172,093
- EBITDA turned positive at $197,355
- Increased market acceptance of patented integrated fixation PEEK implants
- Growth in sales of CustomizedBone™ hydroxyapatite implants
- FDA 510k clearance for partner product NEOS Cranial Loop
- None.
Financial highlights for the six months ended June 30, 2024 and the same period in 2023 include:
- Total revenue of
$1,709,239 $ 1,147,045 49.01% - Gross Margin of
$1,330,965 $871,510 52.7% - Operating profit of
$172,093 $229,345 $401,438 - EBITDA (new metric to report) of
$197,355 $204,691
The increase in profitability was primarily due to increased sales, efficiency improvements and reducing software, insurance and consulting expenses. Sales for the first half of the year have remained strong as additional surgeons request implants with Kelyniam's patented integrated fixation in the PEEK implant product line. Sales from the hydroxyapatite CustomizedBone™ implant with NEOS Cranial Loop fixation also increased as the products continue to gain market acceptance.
Other events occurring in the second quarter included:
- The 2nd annual Shareholder Meeting was held June 26, Ms. Desiree Webb and Mr. Jonathan Thiel were elected to the Board of Directors.
- The company sponsored a number of events at the American Academy of Neurosurgeons meeting in May in
Chicago . Dr. Franco Servadei, an experienced neurotrauma surgeon and former President of the World Federation of Neurological Societies, spoke about the safety and use of hydroxyapatite implants. CustomizedBone™ is the only hydroxyapatite cranial implant indicated for pediatric use in children as young as 7 years of age. - Kelyniam's partner, Fin-Ceramica Faenze, S.p.A., received FDA 510k clearance of the NEOS Cranial Loop for use with CustomizedBone™
Kelyniam Inc., specializes in the rapid production of custom prosthetics utilizing computer aided design and computer aided manufacturing of advanced medical grade polymers. The Company develops, manufactures, and distributes custom cranial and maxillo-facial implants. Kelyniam works directly with surgeons, health systems and payors to improve clinical and cost-of-care outcomes. Kelyniam's web site address is www.Kelyniam.com.
As a cautionary note to investors, certain matters discussed in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such matters involve risks and uncertainties that may cause actual results to differ materially, including the following: changes in economic conditions; general competitive factors; the Company's ability to execute its service and product sales plans; changes in the status of ability to market products; and the risks described from time to time in the Company's SEC reports.
View original content:https://www.prnewswire.com/news-releases/kelyniam-global-releases-strong-q2-financials-302219242.html
SOURCE Kelyniam Global Inc
FAQ
What was Kelyniam Global's (KLYG) revenue for the first half of 2024?
How much did Kelyniam Global's (KLYG) operating profit improve in the first half of 2024?
What factors contributed to Kelyniam Global's (KLYG) increased profitability in Q2 2024?
What new product received FDA clearance for use with Kelyniam Global's (KLYG) CustomizedBone™?
